KrisVKowdleyMDFACP,FACG,FASGE,AGAF
Gastroenterology • Seattle, WAHepatology & Liver Transplantation
Director, Liver Care Network Swedish
Dr. Kowdley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3216 NE 45th Pl
Ste 212
Seattle, WA 98105Phone+1 206-536-3030Fax+1 206-524-0749
Education & Training
Tufts Medical CenterFellowship, Gastroenterology, 1989 - 1991
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1986 - 1988- Oregon Health & Science University (OHSU Health)Internship, Internal Medicine, 1985 - 1986
Icahn School of Medicine at Mount SinaiClass of 1985
Certifications & Licensure
OR State Medical License 1986 - Present
WA State Medical License 1993 - 2026
OH State Medical License 1991 - 1994- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
- Elected Member The American Society for Clinical Investigation, 2006
- Join now to see all
Clinical Trials
- IdB 1016 Treatment for Hepatitis C Disease Start of enrollment: 2003 Nov 01
- Iron Depletion Therapy for Type 2 DM and NAFLD Start of enrollment: 2005 Sep 01
- Effect of Omega-3 PUFA Supplementation in NAFLD Patients Start of enrollment: 2005 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.M Alan Brookhart, Tracy J Mayne, Charles Coombs, Alexander Breskin, Erik Ness
Hepatology. 2024-12-02 - Correction to COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.Kris V Kowdley, Gideon M Hirschfield, Charles Coombs, Elizabeth S Malecha, Leona Bessonova
The American Journal of Gastroenterology. 2024-11-29 - 4 citationsPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, Marco Carbone, Emma Culver
Hepatology. 2024-11-01
Journal Articles
- Diagnosis and Management of Primary Biliary CholangitisZobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
Other
- Treatment of primary sclerosing cholangitisKowdley KV
http://www.uptodate.com/contents/treatment-of-primary-sclerosing-cholangitis
UpToDate, Wolters Kluwer Health - 2013-02-26 - Clinical manifestations and diagnosis of primary sclerosing cholangitisKowdley KV
http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-primary-sclerosing-cholang
UpToDate, Wolters Kluwer Health - 2013-01-28 - Recurrent pyogenic cholangitisKowdley KV, Lee H
http://www.uptodate.com/contents/recurrent-pyogenic-cholangitis
UpToDate, Wolters Kluwer Health - 2012-11-28 - Join now to see all
Press Mentions
Iqirvo® (Elafibranor) Data Shows Efficacy and Safety for up to 3 Years in Patients with PBC with Improvements in Fatigue and PruritusNovember 15th, 2024- Findings from COBALT Trial, Including External Control Arm, Published in the American Journal of GastroenterologySeptember 6th, 2024
- CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate UpdateNovember 14th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
- American Association for the Study of Liver Disease - AASLDFellow
Other Languages
- Tamil
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
